Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
260 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape. Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory). - The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Idiopathic Pulmonary Fibrosis Overview 7 Therapeutics Development 8 Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies 10 Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 14 Idiopathic Pulmonary Fibrosis - Pipeline Products Glance 15 Idiopathic Pulmonary Fibrosis - Products under Development by Companies 18 Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 23 Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 24 Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 76 Drug Profiles 89 Idiopathic Pulmonary Fibrosis - Dormant Projects 237 Idiopathic Pulmonary Fibrosis - Discontinued Products 241 Idiopathic Pulmonary Fibrosis - Product Development Milestones 242 Appendix 249
List of Tables
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2016 18 Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2016 19 Number of Products under Development by Companies, H2 2016 20 Number of Products under Development by Companies, H2 2016 (Contd..1) 21 Number of Products under Development by Companies, H2 2016 (Contd..2) 22 Number of Products under Development by Companies, H2 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2016 24 Comparative Analysis by Late Stage Development, H2 2016 25 Comparative Analysis by Clinical Stage Development, H2 2016 26 Comparative Analysis by Early Stage Development, H2 2016 27 Products under Development by Companies, H2 2016 28 Products under Development by Companies, H2 2016 (Contd..1) 29 Products under Development by Companies, H2 2016 (Contd..2) 30 Products under Development by Companies, H2 2016 (Contd..3) 31 Products under Development by Companies, H2 2016 (Contd..4) 32 Products under Investigation by Universities/Institutes, H2 2016 33 Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2016 34 Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 35 Idiopathic Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 36 Idiopathic Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 37 Idiopathic Pulmonary Fibrosis - Pipeline by ARMO Biosciences, Inc., H2 2016 38 Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp., H2 2016 39 Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2016 40 Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2016 41 Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 42 Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 43 Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2016 44 Idiopathic Pulmonary Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016 45 Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2016 46 Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H2 2016 47 Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 48 Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2016 49 Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2016 50 Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2016 51 Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2016 52 Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016 53 Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2016 54 Idiopathic Pulmonary Fibrosis - Pipeline by GNI Group Ltd., H2 2016 55 Idiopathic Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016 56 Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2016 57 Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2016 58 Idiopathic Pulmonary Fibrosis - Pipeline by Immunomet Therapeutics, Inc. , H2 2016 59 Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H2 2016 60 Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 61 Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2016 62 Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2016 63 Idiopathic Pulmonary Fibrosis - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 64 Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 65 Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H2 2016 66 Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2016 67 Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2016 68 Idiopathic Pulmonary Fibrosis - Pipeline by Novartis AG, H2 2016 69 Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H2 2016 70 Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 71 Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2016 72 Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 73 Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016 74 Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H2 2016 75 Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2016 76 Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H2 2016 77 Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H2 2016 78 Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H2 2016 79 Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics, Inc., H2 2016 80 Idiopathic Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H2 2016 81 Idiopathic Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 82 Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H2 2016 83 Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H2 2016 84 Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2016 85 Assessment by Monotherapy Products, H2 2016 86 Number of Products by Stage and Target, H2 2016 88 Number of Products by Stage and Mechanism of Action, H2 2016 92 Number of Products by Stage and Route of Administration, H2 2016 96 Number of Products by Stage and Molecule Type, H2 2016 98 Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2016 247 Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2016 248 Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2016 249 Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2016 250 Idiopathic Pulmonary Fibrosis - Discontinued Products, H2 2016 251
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
